Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Sep 14, 2013; 19(34): 5693-5699
Published online Sep 14, 2013. doi: 10.3748/wjg.v19.i34.5693
Published online Sep 14, 2013. doi: 10.3748/wjg.v19.i34.5693
Polymorphism in the interleukin-17A promoter contributes to gastric cancer
Alireza Rafiei, Abuzar Ghorbani, Abulghasem Ajami, Touraj Farzmandfar, Maedeh Darzyani Azizi, Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari 48175-1665, Iran
Vahid Hosseini, Department of Internal Medicine, Imam Hospital, Sari 48175-1665, Iran
Ghasem Janbabai, Hematology and Oncology Ward, Department of Internal Medicine, Imam Hospital, Mazandaran University of Medical Sciences, Sari 48175-1665, Iran
Jeremy J Gilbreath, D Scott Merrell, Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, United States
Author contributions: All the authors contributed to this article.
Supported by The Mazandaran University of Medical Sciences, No. 89-512
Correspondence to: Dr. Vahid Hosseini, Department of Internal Medicine, Imam Hospital, Amir Mazandarani St, Sari 48175-1665, Iran. dr.vahid47@gmail.com
Telephone: +98-151-3543088 Fax: +98-151-3543087
Received: December 5, 2012
Revised: March 25, 2013
Accepted: March 28, 2013
Published online: September 14, 2013
Revised: March 25, 2013
Accepted: March 28, 2013
Published online: September 14, 2013
Core Tip
Core tip: There is currently a need for genetic markers to identify individuals at risk for developing gastric cancer. In this study, we describe one such marker, a G-197A polymorphism in the interleukin-17A (IL-17A) promoter. Within our study population, individuals who carry the G-197A polymorphism in the IL-17A promoter region may be at a significantly greater risk of developing gastric cancer. Importantly, the presence of this polymorphism alone was sufficient to increase risk of gastric cancer development.